| 2026-07-29 | Press release | Glaukos Announces Second Quarter 2026 Financial Results |
| 2026-07-29 | Press release | Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 |
| 2026-07-28 | Press release | GAAP to Non-GAAP Recs |
| 2026-07-27 | Press release | Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt |
| 2026-06-25 | Press release | Download , Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis, June |
| 2026-06-25 | Press release | Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis |
| 2026-06-09 | Presentation | Download
PDF file, (opens in new window) |
| 2026-05-26 | Press release | Glaukos Announces Participation in Upcoming Investor Conferences |
| 2026-05-12 | Press release | Download , Glaukos Announces Participation in Upcoming Investor Conferences, May 12, 2026, (opens in new window) |
| 2026-04-29 | Press release | Download
(opens in new window) |
| 2026-04-29 | Earnings deck | Quarterly Summary
of Q1 2026, PDF file, (opens in new window) |
| 2026-04-28 | Financial supplement | GAAP to Non-GAAP Recs
of Q1 2026, PDF file, (opens in new window) |
| 2026-04-16 | Press release | Download , Glaukos Announces the Release of its 2025 Sustainability Report, April 16, 2026, (opens in new window) |
| 2026-04-15 | Press release | Download , Glaukos Receives Permanent J-code for Epioxa™, April 15, 2026, (opens in new window) |
| 2026-04-10 | Press release | Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) |
| 2026-04-08 | Press release | Download , Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29, April 8, 2026, (opens |
| 2026-04-06 | Press release | Download , Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surg |
| 2026-03-19 | Press release | Download , Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratocon |
| 2026-03-19 | Press release | Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care |
| 2026-02-17 | Press release | Download , Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results, February 17, 2026, (opens in new windo |
| 2026-02-17 | Earnings deck | Q4 |
| 2026-02-16 | Financial supplement | Q4 |
| 2026-01-28 | Press release | Download , Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR, January 28, |
| 2026-01-20 | Press release | Download , Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17, Jan |
| 2026-01-13 | Press release | Download , Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Reven |
| 2025-12-16 | Press release | Glaukos Announces Participation in J.P. Morgan Healthcare Conference |
| 2025-11-03 | Press release | Glaukos Announces Participation in Upcoming Investor Conferences |
| 2025-10-29 | Press release | Glaukos Announces Third Quarter 2025 Financial Results |
| 2025-10-20 | Press release | Glaukos Announces FDA Approval of Epioxa™ |
| 2025-10-14 | Press release | Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting |
| 2025-10-08 | Press release | Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 |
| 2025-05-29 | Regulatory report | 2024 EEO-1 REPORT
(opens in new window) |
| 2025-02-19 | Financial supplement | Q4 |
| 2024-11-04 | Earnings deck | Q3 |
| 2024-11-01 | Financial supplement | Q3 |
| 2024-08-02 | Financial supplement | Q2 |
| 2024-07-31 | Earnings deck | Q2 |
| 2024-04-30 | Financial supplement | Q1 |
| 2024-02-20 | Financial supplement | Q4 |
| 2023-11-01 | Earnings deck | Q3 |